The history and conduct of safety assessment of marketed medicines studies in the UK

International Journal of Pharmaceutical Medicine

Volumn 12, Issue 4, 1998, Pages 181-183

  Palmer, L ^a  

^a Novartis Pharmaceuticals UK Ltd   (United Kingdom)

Author keywords

Adverse drug reaction reporting systems; Drug monitoring; Postmarketing; Product surveillance

Indexed keywords

ARTICLE; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; MONITORING; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED KINGDOM;

EID: 0031718547     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Rawlins MD, Jefferys DB. Study of United Kingdom product licence applications containing new active substances, 1987-89. Br Med J 1991; 302:223-225.
2. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? J R Coll Physicians Lond 1995; 29:41-49.
3. The Lancet Commission on Anaesthetics. Report of the Lancet Commission appointed to investigate the subject of the administration of chloroform and other anaesthetics from a clinical standpoint. Lancet 1893; i:629-638.
4. Joint Committee of the Association of the British Pharmaceutical Industry, British Medical Association, Committee on Safety of Medicines and Royal College of General Practitioners. Guidelines on postmarketing surveillance. Br Med J 1988; 296:399-400.
5. Waller PC, Wood SM, Langman MJS, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. Br Med J 1992; 304:1470-1472.
6. Medicines Control Agency. Committee on Safety of Medicines, Royal College of Physicians, British Medical Association and Association of the British Pharmaceutical Industry. Guidelines for company-sponsored safety assessment of marketed medicines. Br J Clin Pharmacol 1994; 38:93-97.
7. European Commission. Draft notice to applicants. 1994; 85-90.
8. La Puma J, Stocking CB, Rhoades WD, Darling CM, Ferner RE, Neuberger J et al. Financial ties as part of informed consent to postmarketing research. Br Med J 1995; 310:1660-1663.
9. Waller PC, Wood SM, Breckenridge AM, Rawlins MD. Why the safety assessment of marketed medicines (SAMM) guidelines are needed. Br J Clin Pharmacol 1994; 38: 93.
10. Medicines Control Agency. Studying the safety of marketed medicines. Mail 1997; 104:5-6.
11. Bloom BM. The rate of contemporary drug discovery. Lex et Scientia 1971; 8:1-11.